Wells Fargo & Company Begins Coverage on Avantor (NYSE:AVTR)

Wells Fargo & Company started coverage on shares of Avantor (NYSE:AVTR) in a report released on Tuesday, Marketbeat reports. The brokerage issued an overweight rating and a $30.00 price target on the stock.

Other research analysts have also issued reports about the stock. Robert W. Baird boosted their price target on shares of Avantor from $26.00 to $27.00 and gave the company an outperform rating in a research report on Monday, July 29th. Barclays boosted their price target on shares of Avantor from $25.00 to $28.00 and gave the company an overweight rating in a research report on Monday, July 29th. Stifel Nicolaus upped their target price on shares of Avantor from $27.00 to $28.00 and gave the stock a buy rating in a research report on Monday, July 29th. Evercore ISI cut their target price on shares of Avantor from $28.00 to $27.00 and set an outperform rating for the company in a research report on Tuesday, July 2nd. Finally, Royal Bank of Canada reiterated an outperform rating and issued a $31.00 target price on shares of Avantor in a research report on Monday, July 29th. Four investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of Moderate Buy and an average price target of $27.40.

Avantor Stock Up 0.2 %

AVTR opened at $25.84 on Tuesday. The company has a fifty day moving average price of $23.42 and a 200-day moving average price of $24.12. The firm has a market capitalization of $17.55 billion, a P/E ratio of 66.08, a price-to-earnings-growth ratio of 2.71 and a beta of 1.32. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.59 and a quick ratio of 1.05. Avantor has a one year low of $16.63 and a one year high of $28.00.

Avantor (NYSE:AVTR) last released its quarterly earnings results on Friday, July 26th. The company reported $0.25 EPS for the quarter, beating analysts’ consensus estimates of $0.23 by $0.02. The firm had revenue of $1.70 billion during the quarter, compared to analyst estimates of $1.70 billion. Avantor had a net margin of 5.28% and a return on equity of 12.40%. Equities research analysts expect that Avantor will post 1.01 earnings per share for the current fiscal year.

Institutional Trading of Avantor

Hedge funds have recently added to or reduced their stakes in the business. Versant Capital Management Inc lifted its stake in Avantor by 2,003.6% in the second quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock worth $25,000 after purchasing an additional 1,102 shares during the last quarter. Blue Trust Inc. raised its stake in shares of Avantor by 1,830.3% during the second quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock valued at $31,000 after acquiring an additional 1,391 shares during the last quarter. Gladius Capital Management LP bought a new position in shares of Avantor during the fourth quarter valued at about $42,000. Montag A & Associates Inc. bought a new position in shares of Avantor during the fourth quarter valued at about $43,000. Finally, TFO Wealth Partners LLC raised its stake in shares of Avantor by 203,100.0% during the fourth quarter. TFO Wealth Partners LLC now owns 2,032 shares of the company’s stock valued at $46,000 after acquiring an additional 2,031 shares during the last quarter. 95.08% of the stock is owned by institutional investors.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.